Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer
Korean Journal of Ophthalmology
;
: 355-357, 2011.
Artículo
en Inglés
| WPRIM
| ID: wpr-15768
ABSTRACT
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piperidinas
/
Quinazolinas
/
Agudeza Visual
/
Estudios de Seguimiento
/
Carcinoma de Pulmón de Células no Pequeñas
/
Córnea
/
Enfermedades de la Córnea
/
Microscopía Acústica
/
Diagnóstico Diferencial
/
Relación Dosis-Respuesta a Droga
Tipo de estudio:
Estudio diagnóstico
/
Estudio observacional
/
Estudio pronóstico
Límite:
Adulto
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Korean Journal of Ophthalmology
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS